Financial Results for the quarter and half year ended 30th September, 2025
MODINATUR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Modi Naturals Ltd reported consolidated revenue from operations of ₹15,502.85 lakhs for Q2 FY26, up ~5.8% YoY from ₹14,657.44 lakhs. Consolidated profit after tax jumped to ₹1,048.28 lakhs (vs ₹788.22 lakhs), a strong ~33% YoY growth, with EPS rising to ₹7.87 from ₹5.70. For H1 FY26, consolidated revenue was ₹30,201.59 lakhs (~2.7% growth) while PAT grew ~28% to ₹2,055.61 lakhs. On a standalone basis, Q2 revenue declined ~5.9% to ₹6,227.80 lakhs and PAT rose modestly ~6.4% to ₹262.75 lakhs. Subsidiary Modi Biotech contributed consolidated revenue of ₹8,482.05 lakhs and PAT of ₹744.51 lakhs. Operating cash flow on a standalone basis was healthy at ₹1,952.42 lakhs for H1, and standalone borrowings declined from ₹3,355.78 lakhs to ₹2,215.69 lakhs, reducing leverage. The statutory auditor Doogar & Associates issued an unqualified limited review report with no qualifications, emphasis of matter, or going concern issues.
Sharp consolidated PAT growth (~28-33%) driven by margin expansion and a strong contribution from subsidiary Modi Biotech is positive for shareholders. However, standalone revenue declined in Q2, suggesting weakness in the parent business that investors should monitor. Overall, the results are constructive on profitability.